

Study Number: I20045

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

C Number:

Study Gender:

PWG Approval Date

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Phenanthrene

CAS Number: 85-01-8

I20045

Female

See web page for date of PWG Approval

Date Report Requested: 07/30/2019

Time Report Requested: 12:32:22

Lab: BRT with ILS

Study Number: I20045
 Test Type: TOX
 Route: Oral Gavage
 Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
 Test Compound: Phenanthrene
 CAS Number: 85-01-8

Date Report Requested: 07/30/2019
 Time Report Requested: 12:32:22
 Lab: BRT with ILS

Female: Immunopath Cohort

	Treatment Groups (mg/kg)							
	0	12.5	25	50	100	200	400	800
Disposition Summary								
Animals Initially In Study	8	8	8	8	8	8	8	8
Early Deaths								
Euthanized, moribund			2	2	3	1		
Found Dead				1				
Removal, See Text Comments								8
Survivors								
Scheduled sacrifice, terminal (SD 28)	8	8	6	5	5	7	8	
Animals Examined Microscopically	8	8	6	5	5	7	8	
ALIMENTARY SYSTEM								
ESOPHAGUS	(1)	(0)	(0)	(1)	(0)	(4)	(1)	(0)
INFLAMMATION; CHRONIC	1 (100%)			1 (100%)		4 (100%)	1 (100%)	
LIVER	(8)	(8)	(6)	(5)	(5)	(7)	(8)	(0)
CARDIOVASCULAR SYSTEM								
No Tissues/Organs Examined								
ENDOCRINE SYSTEM								
ADRENAL GLAND, RIGHT	(8)	(8)	(6)	(5)	(5)	(7)	(8)	(0)
ACCESSORY ADRENOCORTICAL NODULE				1 (20%)		1 (14%)	2 (25%)	
HYPERPLASIA; SUBCAPSULAR	8 (100%)	7 (88%)	6 (100%)	5 (100%)	5 (100%)	7 (100%)	8 (100%)	
GENERAL BODY SYSTEM								
No Tissues/Organs Examined								
GENITAL SYSTEM								
OVARY, LEFT	(8)	(8)	(6)	(5)	(5)	(7)	(8)	(0)

Study Number: I20045

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Date Report Requested: 07/30/2019

Test Type: TOX

Test Compound: Phenanthrene

Time Report Requested: 12:32:22

Route: Oral Gavage

CAS Number: 85-01-8

Lab: BRT with ILS

Species/Strain: Mouse/B6C3F1/N

Female: Immunopath Cohort

	Treatment Groups (mg/kg)							
	0	12.5	25	50	100	200	400	800
HEMATOLYMPHOID SYSTEM								
BALT	(8)	(8)	(6)	(5)	(5)	(7)	(8)	(0)
BONE MARROW	(8)	(8)	(6)	(5)	(5)	(7)	(8)	(0)
LYMPH NODE, MESENTERIC	(8)	(8)	(6)	(5)	(5)	(6)	(8)	(0)
LYMPH NODE, POPLITEAL	(7)	(8)	(6)	(4)	(5)	(7)	(8)	(0)
MEDULLARY SINUSES; INCREASED NUMBER; NEUTROPHIL							1 (13%)	
SPLEEN	(8)	(8)	(6)	(5)	(5)	(7)	(8)	(0)
FOLLICLES; GERMINAL CENTER; INCREASED NUMBER							1 (13%)	
THYMUS	(8)	(8)	(6)	(5)	(5)	(7)	(8)	(0)
CYST	6 (75%)	5 (63%)	4 (67%)	3 (60%)	4 (80%)	7 (100%)	8 (100%)	
ECTOPIC TISSUE						1 (14%)	2 (25%)	
INTEGUMENTARY SYSTEM								
No Tissues/Organs Examined								
MUSCULOSKELETAL SYSTEM								
BONE, FEMUR	(1)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
BONE, FEMUR, LEFT	(7)	(8)	(6)	(5)	(5)	(7)	(8)	(0)
NERVOUS SYSTEM								
No Tissues/Organs Examined								
RESPIRATORY SYSTEM								
LUNG	(8)	(8)	(6)	(5)	(5)	(7)	(8)	(0)
CONGESTION	1 (13%)	2 (25%)		2 (40%)	2 (40%)	1 (14%)	1 (13%)	
INFILTRATE, CELLULAR; HISTIOCYTE							1 (13%)	
ARTERY, PULMONARY; INFLAMMATION; CHRONIC-ACTIVE			1 (17%)					
PLEURA; INFLAMMATION; CHRONIC- ACTIVE		2 (25%)	1 (17%)					
INFLAMMATION; CHRONIC-ACTIVE				1 (20%)		1 (14%)	1 (13%)	

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 07/30/2019
Time Report Requested: 12:32:22
Lab: BRT with ILS

Female: Immunopath Cohort

Treatment Groups (mg/kg)

0 12.5 25 50 100 200 400 800

SPECIAL SENSES SYSTEM

No Tissues/Organs Examined

URINARY SYSTEM

KIDNEY, RIGHT	(8)	(8)	(6)	(5)	(5)	(7)	(8)	(0)
INFLAMMATION; CHRONIC			2 (33%)	1 (20%)	2 (40%)		1 (13%)	
PAPILLA; MINERALIZATION			1 (17%)					
NEPHROPATHY		1 (13%)				1 (14%)	3 (38%)	

Study Number: I20045

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Phenanthrene

CAS Number: 85-01-8

Date Report Requested: 07/30/2019

Time Report Requested: 12:32:22

Lab: BRT with ILS

LEGEND

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD – Study Day

**** END OF REPORT ****